40065-09-6

Basic information

• Product Name: 2-(4-Bromo-2,6-dichloroanilino)-2-imidazoline
• Synonyms: 2-(4-Bromo-2,6-dichloroanilino)-2-imidazoline;ST-871
• CAS NO: 40065-09-6
• Molecular Formula: C₉H₈BrCl₂N₃
• Molecular Weight: 308.99
• Mol File: 40065-09-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-Bromo-2,6-dichloroanilino)-2-imidazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Bromo-2,6-dichloroanilino)-2-imidazoline(40065-09-6)
• EPA Substance Registry System: 2-(4-Bromo-2,6-dichloroanilino)-2-imidazoline(40065-09-6)

Safety Data

• Hazardous Substances Data: 40065-09-6(Hazardous Substances Data)

Upstream product

• 4205-90-7 Clonidine 
• 61939-88-6 2-[N-propargyl-N-(2',6'-dichloro-4'-bromo-phenyl)-amino]-2-imidazoline 

Relevant articles and documents

Predictable site-selective functionalization: Promoter group assistedpara-halogenation ofN-substituted(hetero)aromatics under metal-free condition

Herein, regioselectivepara-C-H halogenation ofN-pyrimidyl (hetero)aromatics through SEAr (electrophilic aromatic substitution) type reaction is disclosed. SEAr type reaction has been utilized for the C5-bromination of indolines (para-selective) withN-bromosuccinimide under metal and additive-free conditions in good to excellent yields. The developed methodology is also applicable for iodination and challenging chlorination. The pyrimidyl group is identified as a reactivity tuner that also controls the regioselectivity. The present method is also applicable for selective halogenation of aniline, pyridine, indole, oxindole, pyrazole, tetrahydroquinoline, isoquinoline, and carbazole. DFT studies such as Fukui nucleophilicity and natural charge maps also support the observedp-selectivity. Post-functionalization of the title compound into the corresponding arylated, olefinated, and dihalogenated products is achieved in a one-pot, two-step fashion. Late-stage C-H bromination was also executed on drug/natural molecules (harmine, etoricoxib, clonidine, and chlorzoxazone) to demonstrate the applicability of the developed protocol.

Pharmaceutical compositions containing a 5-oxo-2,3-dihydro-imidazo[1,2-a]-s-triazine and method of use

Pharmaceutical compositions containing, as an active ingredient, a compound of the formula SPC1 Wherein R1 is phenyl or mono-, di or tri-substituted phenyl, the substituents being each halogen, methyl, methoxy or trifluoromethyl, and R2 is hydrogen, phenyl or halo-phenyl; And a method of using the same as antidepressants.